StockData
Liquidia Corp logo

Liquidia Corp (LQDA) shareholders

LQDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/3075% above fair value
$56.73+0.36 (+0.64%)

Close on Nov 17, 2026Market cap $5.08BP/E 40.8Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
81.1%
73M of 90M shares
Institutional holders
336
129 new, 33 sold out
Net institutional buying
11M
In Q2 2026
Insider trades, 12 months
1 buys · 170 sales
Net sold $226.63M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
BlackRock, Inc.10,551,90111.90%13G (passive) amendmentJun 30, 2026
Short Daniel S.
Joint filing with Wehrly, Mark C. (9.90%), Saito Edric C. (9.90%) and 15 more
8,656,0389.90%13G (passive) amendmentDec 31, 2025
Dapice Joshua J.
Joint filing with Wehrly, Mark C. (9.95%), Short Daniel S. (9.95%) and 17 more
8,565,6389.95%13G (passive) amendmentSep 30, 2025
Spokes, Andrew J. M.
Joint filing with Farallon Capital Management, L.L.C. (9.40%), Dapice Joshua J. (9.40%) and 13 more
8,365,0389.40%13G (passive) amendmentJun 30, 2026
Caligan Partners LP
Joint filing with David Johnson (9.80%)
8,118,5929.60%13D (active) amendmentSep 10, 2024
Warren, John R.
Joint filing with Wehrly, Mark C. (8.00%), Dapice Joshua J. (8.00%) and 15 more
6,832,4728.00%13G (passive)Jul 7, 2025
Paul B Manning4,946,7716.50%13G (passive) amendmentJun 30, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of LQDAValueChange% of portfolio
BlackRock, Inc.10,788,58612.05%$860.17M+5,299,4420.01%
Farallon Capital Management LLC8,365,0389.35%$666.94M−291,0003.08%
Caligan Partners LP8,118,8929.07%$647.32M–30.45%
Findell Capital Management LLC3,502,1123.91%$279.22M–39.31%
Vanguard Capital Management LLC3,139,1833.51%$250.29M+212,2380.01%
State Street Corp3,030,3953.39%$241.61M+1,148,7960.01%
Opaleye Management Inc.2,447,5002.73%$195.14M−97,50017.67%
Geode Capital Management, LLC2,121,2902.37%$169.16M+192,3210.01%
Bank Of America Corp /De/1,991,5662.22%$158.79M−296,2260.01%
Price T Rowe Associates Inc /Md/1,940,3642.17%$154.71M+987,2130.02%
Vanguard Portfolio Management LLC1,532,1511.71%$122.16M+899,5260.01%
Caprock Group, LLC1,409,7591.57%$112.40M+42,5242.15%
Mpm Bioimpact LLC1,386,1741.55%$110.52M−18,9846.74%
D. E. Shaw & Co., Inc.1,267,7061.42%$101.07M+394,6410.05%
Fuller & Thaler Asset Management, Inc.1,209,6041.35%$96.44MNew0.26%
Goldman Sachs Group Inc958,8921.07%$76.45M+146,9020.01%
Federated Hermes, Inc.816,1870.91%$65.07M+377,4200.09%
Northern Trust Corp709,0630.79%$56.53M+129,1880.01%
Charles Schwab Investment Management Inc674,0330.75%$53.74M+116,8330.01%
Morgan Stanley658,4410.74%$52.50M+313,7700.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202633673M81.1%129 / 10380 / 3317M6M
Q1 202624462M68.8%55 / 7778 / 3611M8M
Q4 202522762M69.1%61 / 7072 / 338M11M
Q3 202519965M72.2%52 / 6559 / 3019M12M
Q2 202517758M64.3%37 / 6457 / 2710M8M
Q1 202516855M61.7%28 / 6550 / 2210M6M
Q4 202416452M57.6%31 / 6838 / 197M9M
Q3 202415453M59.0%36 / 5145 / 1715M4M
Q2 202413746M51.9%29 / 5932 / 295M6M
Q1 202413948M53.2%43 / 4536 / 1915M4M
Q4 202311637M41.0%30 / 4331 / 1611M3M
Q3 202310229M31.9%18 / 3134 / 182M3M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

231 funds held LQDA in Q2 2026, 65% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of LQDAValue% of fundAs of
iShares Core S&P Small-Cap ETF4,232,4224.73%$337.45M0.30%Jun 30, 2026
Vanguard Total Stock Market Index Fund2,259,2892.52%$180.13M0.01%Jun 30, 2026
iShares Russell 2000 ETF1,811,4742.02%$144.43M0.17%Jun 30, 2026
Fullerthaler Behavioral Small-Cap Growth812,8000.91%$64.80M1.05%Jun 30, 2026
Vanguard Extended Market Index Fund805,8800.90%$64.25M0.07%Jun 30, 2026
Fidelity Small Cap Index Fund771,3650.86%$64.88M0.19%Jul 31, 2026
iShares Russell 2000 Growth ETF651,4930.73%$51.94M0.34%Jun 30, 2026
State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF643,8370.72%$51.33M0.30%Jun 30, 2026
iShares S&P Small-Cap 600 Growth ETF631,3180.71%$50.33M0.61%Jun 30, 2026
T. Rowe Price New Horizons Fund, Inc.521,7060.58%$41.60M0.28%Jun 30, 2026
Small Cap Growth Fund413,5110.46%$34.78M0.62%Jul 31, 2026
State Street(R) SPDR(R) S & P 600(TM) Small Cap Growth ETF398,5800.45%$31.78M0.61%Jun 30, 2026
Oberweis Micro-Cap Fund392,1000.44%$31.26M1.94%Jun 30, 2026
Vanguard Tax-Managed Small-Cap Fund388,0920.43%$30.94M0.27%Jun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.364,9520.41%$29.10M0.24%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Roger JeffsChief Executive Officer, Director2,167,5152.42%Oct 13, 2026
Jason AdairChief Business Officer177,2690.20%Oct 28, 2026
Dana BoyleChief Accounting Officer164,0280.18%Oct 28, 2026
Russell SchundlerGeneral Counsel617,3410.69%Oct 13, 2026
Rajeev SaggarChief Medical Officer141,4670.16%Oct 13, 2026
Michael KasetaCFO and COO340,1480.38%Oct 13, 2026
Sanjeev KhindriChief Development Officer64,8460.07%Oct 13, 2026
Sarah KreppChief Human Resource Officer115,2410.13%Oct 13, 2026
Scott MoomawChief Commercial Officer181,4870.20%Oct 13, 2026
Stephen M. BlochDirector104,5700.12%Oct 7, 2026
Raman SinghDirector53,1050.06%Sep 15, 2026
Katherine Rielly-GauvinDirector56,3640.06%Aug 21, 2026
Arthur S. KirschDirector46,6370.05%Jun 18, 2026
Paul B. ManningDirector673,8780.75%Jun 18, 2026
Partners LP CaliganDirector, 10% owner8,163,2299.12%Jun 18, 2026
Joanna HorobinDirector39,6370.04%Jun 18, 2026
Damian deGoaDirector92,3530.10%Jun 18, 2026
David Edward JohnsonDirector, 10% owner8,157,3479.11%Jun 18, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Dana Boyle
Chief Accounting Officer
Oct 26, 2026Sale(10b5-1 plan)−1,581$43.19$68.28K164,028
Jason Adair
Chief Business Officer
Oct 26, 2026Sale(10b5-1 plan)−688$43.19$29.71K177,269
Russell Schundler
General Counsel
Oct 12, 2026Sale(10b5-1 plan)−13,692$28.48$389.95K602,841
Rajeev Saggar
Chief Medical Officer
Oct 12, 2026Sale(10b5-1 plan)−9,218$28.48$262.53K126,368
Scott Moomaw
Chief Commercial Officer
Oct 12, 2026Sale(10b5-1 plan)−8,863$28.48$252.42K181,487
Sarah Krepp
Chief Human Resource Officer
Oct 12, 2026Sale(10b5-1 plan)−5,245$28.48$149.38K115,241
Sanjeev Khindri
Chief Development Officer
Oct 12, 2026Sale(10b5-1 plan)−1,101$28.48$31.36K64,846
Michael Kaseta
CFO and COO
Oct 12, 2026Sale(10b5-1 plan)−18,938$28.48$539.35K340,148
Roger Jeffs
Chief Executive Officer, Director
Oct 12, 2026Sale(10b5-1 plan)−32,744$28.48$932.55K1,125,848
Dana Boyle
Chief Accounting Officer
Oct 12, 2026Sale(10b5-1 plan)−5,892$28.48$167.80K165,609
Jason Adair
Chief Business Officer
Oct 12, 2026Sale(10b5-1 plan)−7,301$28.48$207.93K177,957
Russell Schundler
General Counsel
Oct 9, 2026Option exercise+6,409––616,533
Russell Schundler
General Counsel
Oct 9, 2026Option exercise+3,758––610,124
Rajeev Saggar
Chief Medical Officer
Oct 9, 2026Option exercise+4,486––135,586
Rajeev Saggar
Chief Medical Officer
Oct 9, 2026Option exercise+3,530––131,100
Scott Moomaw
Chief Commercial Officer
Oct 9, 2026Option exercise+4,358––190,350
Scott Moomaw
Chief Commercial Officer
Oct 9, 2026Option exercise+3,108––185,992
Sarah Krepp
Chief Human Resource Officer
Oct 9, 2026Option exercise+3,178––120,486
Michael Kaseta
CFO and COO
Oct 9, 2026Option exercise+7,049––359,086
Michael Kaseta
CFO and COO
Oct 9, 2026Option exercise+5,828––352,037
Roger Jeffs
Chief Executive Officer, Director
Oct 9, 2026Option exercise+14,333––1,158,592
Roger Jeffs
Chief Executive Officer, Director
Oct 9, 2026Option exercise+13,833––1,144,259
Dana Boyle
Chief Accounting Officer
Oct 9, 2026Option exercise+3,178––171,501
Jason Adair
Chief Business Officer
Oct 9, 2026Option exercise+3,868––185,258
Jason Adair
Chief Business Officer
Oct 9, 2026Option exercise+2,474––181,390
Jason Adair
Chief Business Officer
Oct 9, 2026Option exercise+3,906––178,916
Stephen M. Bloch
Director
Oct 5, 2026Sale−235,477$27.13$6.39M0
Raman Singh
Director
Sep 14, 2026Option exercise+8,468$9.31$78.84K53,105
Raman Singh
Director
Sep 14, 2026Sale−8,468$66.16$560.24K44,637
Raman Singh
Director
Sep 11, 2026Option exercise+556$8.63$4.80K45,193
Raman Singh
Director
Sep 11, 2026Option exercise+8,468$9.31$78.84K53,661
Raman Singh
Director
Sep 11, 2026Sale−9,024$68.62$619.23K44,637
Sarah Krepp
Chief Human Resource Officer
Sep 1, 2026Sale(10b5-1 plan)−274$67.76$18.57K117,308
Jason Adair
Chief Business Officer
Aug 21, 2026Option exercise+9,000$9.31$83.79K225,438
Jason Adair
Chief Business Officer
Aug 21, 2026Option exercise+11,799$9.31$109.85K237,237
Jason Adair
Chief Business Officer
Aug 21, 2026Option exercise+10,762$14.20$152.82K247,999
Jason Adair
Chief Business Officer
Aug 21, 2026Option exercise+238$14.20$3.38K248,237
Jason Adair
Chief Business Officer
Aug 21, 2026Sale(10b5-1 plan)−31,799$69.09$2.20M216,438
Jason Adair
Chief Business Officer
Aug 21, 2026Sale(10b5-1 plan)−41,832$69.09$2.89M174,606
Katherine Rielly-Gauvin
Director
Aug 20, 2026Option exercise+11,727$2.51$29.43K56,364
Katherine Rielly-Gauvin
Director
Aug 20, 2026Option exercise+6,666$2.59$17.26K63,030
Katherine Rielly-Gauvin
Director
Aug 20, 2026Sale(10b5-1 plan)−18,393$72.23$1.33M44,637
Katherine Rielly-Gauvin
Director
Aug 19, 2026Option exercise+23,455$2.51$58.87K68,092
Katherine Rielly-Gauvin
Director
Aug 19, 2026Sale(10b5-1 plan)−36,789$74.99$2.76M44,637
Katherine Rielly-Gauvin
Director
Aug 19, 2026Option exercise+13,334$2.59$34.54K81,426
Rajeev Saggar
Chief Medical Officer
Aug 19, 2026Option exercise+50,000$3.73$186.50K192,265
Rajeev Saggar
Chief Medical Officer
Aug 19, 2026Sale−50,000$74.06$3.70M142,265
Rajeev Saggar
Chief Medical Officer
Aug 17, 2026Sale−29,534$76.84$2.27M142,265
Jason Adair
Chief Business Officer
Jul 27, 2026Sale(10b5-1 plan)−688$87.53$60.22K216,438
Dana Boyle
Chief Accounting Officer
Jul 27, 2026Sale(10b5-1 plan)−1,600$87.53$140.05K167,919
Stephen M. Bloch
Director
Jul 23, 2026Sale−96,400$89.44$8.62M505,077
Stephen M. Bloch
Director
Jul 23, 2026Sale−3,600$90.71$326.56K501,477
Stephen M. Bloch
Director
Jul 22, 2026Sale−14,562$89.24$1.30M601,477
Stephen M. Bloch
Director
Jul 22, 2026Sale−48,032$88.65$4.26M616,039
Stephen M. Bloch
Director
Jul 22, 2026Sale−37,406$87.70$3.28M664,071
Stephen M. Bloch
Director
Jul 21, 2026Sale−74,444$79.98$5.95M702,033
Stephen M. Bloch
Director
Jul 21, 2026Sale−556$80.66$44.85K701,477
Stephen M. Bloch
Director
Jul 20, 2026Sale−3,596$79.55$286.06K776,477
Scott Moomaw
Chief Commercial Officer
Jul 13, 2026Sale(10b5-1 plan)−8,864$71.52$633.95K182,485
Scott Moomaw
Chief Commercial Officer
Jul 13, 2026Sale(10b5-1 plan)−675$71.39$48.19K191,349

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
24.30%
18M shares short
Days to cover
5.3
At 3M shares a day
Change since last report
+1.2%
From 17M shares
Short volume, 20 days
52.8%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Liquidia's stock actually held short. Settlement fails (shares not delivered on time) peaked at 29,000 shares on Sep 3, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Ramandeep Singh
Director
Sep 14, 20268,468$560.24KSep 14, 2026Stock Option Exercise
Ramandeep Singh
Director
Sep 11, 20269,024$619.21KSep 11, 2026Stock Option Exercise
Jason Adair
Officer
Aug 21, 202673,631$5.23MAug 21, 2026Exercise of Stock Options
Katherine Rielly-Gauvin
Director
Aug 19, 202655,182$4.10MAug 19, 2026Exercise of Stock Options
Rajeev Saggar
Officer
Aug 19, 202650,000$3.70MAug 19, 2026Stock Option Exercise
Rajeev Saggar
Officer
Aug 17, 202629,534$2.27MAug 17, 2026Performance Shares
Sarah Krepp
Officer
Jun 11, 202624,880$1.62MJun 11, 2026Employee Stock Purchase Plan
Canaan VIII LP
Director
Jun 10, 2026200,000$13.00MJun 10, 2026pre-IPO investment
Canaan VIII LP
Director
Jun 8, 2026200,000$12.80MJun 8, 2026pre-IPO investment
Canaan VIII LP
Director
Jun 4, 2026200,000$13.00MJun 4, 2026Pre-IPO Investment
Paul B. Manning
Director
Jun 4, 2026200,000$11.14MJun 4, 2026Registered Direct Offering
Arthur S. Kirsch
Director
Jun 1, 202630,000$1.84MJun 1, 2026Market Purchase
Ramandeep Singh
Director
May 21, 202629,494$1.77MMay 21, 2026Stock Option Exercise
Serendipity Biopharma LLC
Director, Officer
May 20, 2026106,428$6.38MMay 20, 2026Merger or Acquisition
Serendipity Biopharma LLC
Director, Officer
May 14, 2026100,000$5.76MMay 14, 2026Merger or Acquisition

See a number that looks wrong?